Journal of Hematology and Oncology Research

Journal of Hematology and Oncology Research special issue is devoted to publishing articles that focus on a specific subject or topic. Special Issue highlights the important research areas and promotes and provides a comprehensive summary of recent advancements in that field.

Ongoing Special Issue Theme of Journal of Hematology and Oncology Research: Advances in Non-Hodgkin Lymphomas

The primary objective of the Special Issue is to bring together professionals from various disciplines to showcase the most recent developments in research and encourage the exchange of knowledge and concepts. It also provides a platform for researchers to explore interdisciplinary methodologies and propose innovative research works. 
 

Dr. Zilu Zhu, Sanford Burnham Prebys Medical Discovery Institute, United States, (Editorial Board Member) of the Journal of Hematology and Oncology Research proposed a Special issue. The theme of the Special Issue is “Advances in Non-Hodgkin Lymphomas”.
 

The special issue welcomes submissions from a variety of disciplines and areas related to the theme. This can include topics such as Markers, Epidemiology, Genetics, Drugs, Cancer therapy, Cancer Care, Case reports, Surgery, Radiology, Pathology, Imaging, Psychosocial, Quality of life, Risk factors. The aim is to provide a platform for researchers, and practitioners to exchange knowledge, explore new strategies and models, and discuss recent advances in the field.

The submission of a special issue manuscript is simple. All you need to do is click here or send it as an e-mail attachment to the Editorial Office at info@openaccesspub.org

Upon acceptance of an article, an Article Processing Charge of $810 USD is levied to cover the costs of publication. The main purpose of the article processing charge is to cover the cost of hosting, submitting, and formatting articles, as well as the copy-editing fees.

Important Note:

• Acceptance period: 14 days from the submitted date
• People involved: Dr. Zilu Zhu - Editor

The special issue welcomes submissions from a variety of disciplines and areas related to the theme  - "Advances in Non-Hodgkin Lymphoma"

Description of the Special Issue:

The emerging challenges and solutions provided by Modern methods are extremely interesting and are of great hope for the future.  This platform brings forth the outstanding research information in the specified field which helps researchers to have a perfect source specifically designed for research on "Diffuse Large B-Cell Lymphoma (DLBCL)" with much emphasis on immunity and cure

This resource not only affects the way the trending research is evolving but also creates tremendous new support for the now working researchers to put forth their work at a worthy and specifically targeted readership for the desired proper usage of the knowledge dissipated by you.

This research area has many new challenges in the future and many challenges still remain to be resolved, and we hope that this issue will help to open new horizons for research on Diffuse Large B-Cell Lymphoma (DLBCL)

Topics of interests include:

• Breast cancer, heterogeneity, human potential, genetic, epigenetic disorders, molecular biology of breast cancer, ESR1 mutation, targeted therapy, immunotherapy.

We look for high quality publications on: "Modern Standards and New Perspectives in Breast Cancer Treatment"

Metrics:

The importance and need for this special issue:
Welcomes submissions to the thematic on "Modern Standards and New Perspectives in Breast Cancer Treatment".

Submission Instructions: All submissions will undergo peer review and accepted articles will be published in Journal of Hematology and Oncology Research (ISSN: 2372-6601). We invite authors to submit their manuscripts to the special issue. Publishing with JHOR must adhere to the standards of international publication ethics guidelines as well as our own standards. Authors are requested to prepare their manuscripts according to the guidelines specified in the “Instructions for Authors” section of our website. 

Description of the Special Issue:
 

Breast cancer (BC) occupies a leading position in the structure of cancer morbidity and mortality. The treatment strategy for this disease has undergone significant changes in recent years. Biologically, breast cancer is an extremely heterogeneous group of diseases characterized by extreme variability of genetic, epigenetic disorders unique to each patient. In 2022, breast cancer was diagnosed in 2.3 million women and caused 670,000 deaths worldwide. Breast cancer occurs worldwide in women of all ages after puberty, with incidence rates increasing with age. Estimates show striking disparities in the burden of breast cancer in different countries according to the level of human development. For example, in countries with a very high Human Development Index (HDI), one in 12 women will be diagnosed with breast cancer in her lifetime and one in 71 women will die from it. On the other hand, in countries with a low HDI, only 1 in 27 women would diagnosed with breast cancer in their lifetime, but 1 in 48 women will die from it.

Breast cancer is a prime example of a malignant cancer whose treatment based on molecular genetic classification, which in turn has led to certain successes, increasing life expectancy and quality of life.

Classically, chemotherapy used for breast cancer. It is an effective method of breast cancer treatment, but it has some disadvantages. Chemo drugs attack not only cancerous but also normal rapidly multiplying cells, so they cause serious side effects. Sometimes tumors develop resistance - they stop responding to chemotherapy.

A relatively new class of drugs - targeted drugs and immunotherapies - helps to solve these problems. Each such drug has a strictly defined target - a molecule that is necessary for uncontrolled multiplication and survival of cancer cells.

Advances in molecular biology and genetics make it possible to perform molecular genetic analysis of tumor cells and select combinations of chemo- drugs that are optimal for a particular woman. This approach called personalized treatment.

Molecular genetic analysis helps to increase the effectiveness of chemotherapy, to help patients who are no longer helped by standard combinations of chemo-drugs.

Currently, modern drugs for the treatment of breast cancer with different mechanisms of action continue to be developed. Common goals for antitumor therapy are to slow the progression and minimize the symptoms of the disease, increase the duration and quality of life of patients.

Thus, despite the recently accumulated data concerning oncogenesis, an active search for new targets continues, the development of drugs to which will significantly increase the effectiveness of breast cancer treatment.